PC/PE/PS Phospholipid Composition for Anti-Tumor TADC Maturation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dendritic cells in the tumor microenvironment, known as tumor-associated dendritic cells (TADC), exhibit an immature phenotype that leads to immunosuppression and reduced anti-tumor activity, contributing to cancer cell escape from immune surveillance.
Innovation Solution
A composition comprising phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS) is administered to induce maturation of immature dendritic cells into mature bone marrow-derived dendritic cells (BMDCs), enhancing anti-tumor immune responses by increasing inflammatory cytokine production and marker expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer immunotherapy is used, then general immune activation is achieved, but tumor-associated dendritic cells remain immature and suppressive
Solution Approach 1:
The patent changes the biochemical parameters of TADC by administering a specific composition of three phospholipids (PC, PE, and PS). This composition alters the membrane composition and signaling pathways of TADC, transforming them from an immature suppressive phenotype to a mature anti-tumor phenotype, thereby resolving the contradiction between maintaining reliability and improving adaptability.
Solution Approach 2:
The invention uses a composite phospholipid composition comprising phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS) in specific ratios. This composite material works synergistically to induce TADC maturation, where each phospholipid component contributes to different aspects of the maturation process, overcoming the limitations of conventional single-agent therapies.
2Object-affected harmful factors
If TADC are present in tumor microenvironment, then immune surveillance is compromised, but eliminating them reduces antigen presentation capability
Solution Approach 1:
Instead of eliminating TADC or suppressing their function, the patent inverts the approach by inducing their maturation. The phospholipid composition transforms TADC from suppressive immature cells into functional mature cells that actively promote anti-tumor immunity, thereby eliminating the harmful suppressive effect while preserving and enhancing the beneficial antigen presentation function.
3Reliability
If phospholipid composition is administered, then TADC maturation is induced, but treatment complexity increases
Solution Approach 1:
The patent simplifies the treatment approach by focusing on changing the phospholipid composition parameters of TADC membranes. By administering a well-defined composition of three natural phospholipids in specific ratios, the treatment achieves reliable TADC maturation without requiring complex delivery systems or combination therapies, thus maintaining simplicity while ensuring efficacy.
Data Source
Figure 1(a)~1(e)
Figure 2
Figure 3(a)~3(c)
AI summary
The present invention aims to provide means to maintain and enhance the anti-tumor activity of TADC in a tumor microenvironment. The present inventors found that when a composition comprising three kinds of phospholipids "cPLs adjuvant" is administered, the degree of growth of tumors implanted to mice was notably suppressed, and confirmed that immature dendritic cells, when cultured in vitro in the presence of the cPLs adjuvant, become mature bone marrow-derived dendritic cells and induce cytokine production.